Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston (Z.I.S., V.G., W.J.H., J.P.S.).
Division of Cardiology, Université de Rennes, CHU Rennes, INSERM, LTSI-UMR 1099, France (V.G.).
Circ Arrhythm Electrophysiol. 2021 Apr;14(4):e009668. doi: 10.1161/CIRCEP.120.009668. Epub 2021 Apr 16.
Symptomatic heart failure (HF) patients despite optimal medical therapy and advances such as invasive hemodynamic monitoring remain challenging to manage. While cardiac resynchronization therapy remains a highly effective therapy for a subset of HF patients with wide QRS, a majority of symptomatic HF patients are poor candidates for such. Recently, cardiac contractility modulation, neuromodulation based on carotid baroreceptor stimulation, and phrenic nerve stimulation have been approved by the US Food and Drug Administration and are emerging as therapeutic options for symptomatic HF patients. This state-of-the-art review examines the role of these evolving electrical therapies in advanced HF.
尽管有最佳的药物治疗和诸如侵入性血流动力学监测等进展,患有症状性心力衰竭(HF)的患者仍难以治疗。虽然心脏再同步治疗仍然是宽 QRS 心力衰竭患者亚组的一种非常有效的治疗方法,但大多数有症状的 HF 患者不适合这种治疗方法。最近,美国食品和药物管理局批准了心脏收缩力调节、基于颈动脉压力感受器刺激的神经调节和膈神经刺激,这些方法正在成为治疗有症状 HF 患者的新选择。本综述探讨了这些新兴电疗方法在晚期 HF 中的作用。